Tag: Atai Life Sciences - Psychedelic Alpha

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Post published:September 14, 2023
Post category:Press Release

atai Life Sciences to Participate in Upcoming September Investor Conferences

Post published:September 6, 2023
Post category:Press Release

Read more about the article atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

Post published:August 10, 2023
Post category:Press Release

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Post published:August 8, 2023
Post category:Press Release

atai Life Sciences to Participate in Upcoming June Investor Conferences

Post published:June 1, 2023
Post category:Press Release

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

Post published:May 11, 2023
Post category:Press Release

atai Life Sciences to Participate in Upcoming May Investor Conference

Post published:May 3, 2023
Post category:Press Release

Read more about the article atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

Post published:April 28, 2023
Post category:Press Release

Read more about the article atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

Post published:April 13, 2023
Post category:Press Release

Read more about the article atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Post published:March 24, 2023
Post category:Press Release

Weekly Bulletin

Your weekly recap of news and analysis from the psychedelic sector.

Colorado Natural Medicine Advisory Bulletin

Everything you need to know about implementing the NMHA in Colorado.

News & Press Releases

The latest news from across the psychedelics space.

Psychedelics Patent Trackers

We track the latest patents and filings related to psilocybin, MDMA and DMT.

Psychedelic Law Trackers

Mapping psychedelic drug policy reform across the United States and worldwide.

Psychedelics Drug Development Tracker

From drug discovery to regulatory approval, we map drug development in psychedelics.

Stocks & Companies Directory

A directory of all the major psychedelics stocks, companies and ETFs.

Sector Landscape Map

Explore the Psychedelic Sector Landscape visually using our new tool.

Stock Watchlist

A one-stop overview of psychedelics stocks financial performance.

atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

atai Life Sciences to Participate in Upcoming September Investor Conferences

atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)

atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences to Participate in Upcoming June Investor Conferences

atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates

atai Life Sciences to Participate in Upcoming May Investor Conference

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting

atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Psychedelic Alpha

Quick Links

Newsletter

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.